Actively Recruiting
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Led by National Cancer Institute (NCI) · Updated on 2026-05-13
500
Participants Needed
27
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that have high expression of the Trop-2, nectin-4, or HER2 proteins and that may have spread from where they first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or to other places in the body (metastatic). Precision medicine is a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, or treat disease in a way that is tailored to the patient. ADCs such as sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan are monoclonal antibodies attached to biologically active drugs and are a form of targeted therapy. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab attaches to a protein called Trop-2 on the surface of tumor cells and delivers govitecan to kill them. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. Trastuzumab deruxtecan is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Personalized treatment with sacituzumab govitecan, enfortumab vedotin, or trastuzumab deruxtecan may be an effective treatment option for patients with advanced or metastatic solid tumors that screen positive for high expression of Trop-2, nectin-4, or HER2, respectively.
CONDITIONS
Official Title
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older with confirmed solid tumors requiring therapy
- Disease not curable by standard treatments or progressed after all available beneficial therapies, or intolerant to such treatments
- Patients must have had RNA testing showing high target expression or submit tissue for RNA testing
- Confirmation of high target protein expression by immunohistochemistry
- Measurable disease by imaging within past 2 months
- Eastern Cooperative Oncology Group performance status 0 to 2
- No history of transfusion dependence or persistent bone marrow suppression
- Adequate liver and kidney function as specified
- Willingness to undergo mandatory biopsies and blood sample collections
- Women of childbearing potential must not be pregnant and agree to use contraception
- Hemoglobin > 9.0 g/dL, leukocytes ≥ 3000/mL, neutrophils ≥ 1500/mL, platelets ≥ 100,000/mL
- No more than 3 prior lines of chemotherapy in advanced/metastatic setting
- Controlled HIV, hepatitis B, and hepatitis C infections as specified
- Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days before enrollment
- Additional criteria specific to treatment cohorts regarding protein expression and contraception
You will not qualify if you...
- Active or progressive brain metastases or leptomeningeal disease
- Significant cardiovascular conditions including congestive heart failure class > 2, unstable angina, recent myocardial infarction, or serious arrhythmias
- Abnormal ECG judged clinically meaningful by investigator
- Active or chronic corneal disorders requiring treatment
- History of allergic reactions to similar compounds as study drugs
- History of interstitial lung disease or pneumonitis requiring steroids
- Grade 2 or higher peripheral neuropathy
- Use of full dose warfarin anticoagulants; low molecular weight heparin or Factor X inhibitors allowed
- Pregnant or breastfeeding women
- Inadequate washout from prior therapies as defined
- Concurrent use of other investigational agents
- Recent systemic corticosteroid use at > 20 mg/day prednisone equivalent
- Unrecovered toxicities from prior anticancer therapy above grade 1 except alopecia
- Prolonged corrected QT interval beyond specified limits
- Uncontrolled infections or intercurrent illnesses
- Recent live vaccine administration
- Other medical or psychiatric conditions that may interfere with study participation
- Cohort-specific exclusions including certain cancer types, prior treatments, and drug interactions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 27 locations
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
Actively Recruiting
2
UC San Diego Health System - Encinitas
Encinitas, California, United States, 92024
Actively Recruiting
3
City of Hope at Irvine Lennar
Irvine, California, United States, 92618
Actively Recruiting
4
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Actively Recruiting
5
UC San Diego Medical Center - Hillcrest
San Diego, California, United States, 92103
Actively Recruiting
6
Yale University
New Haven, Connecticut, United States, 06520
Actively Recruiting
7
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut, United States, 06611
Actively Recruiting
8
UF Health Cancer Institute - Gainesville
Gainesville, Florida, United States, 32610
Actively Recruiting
9
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
10
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, United States, 40536
Actively Recruiting
11
Ochsner Medical Center Jefferson
New Orleans, Louisiana, United States, 70121
Actively Recruiting
12
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
13
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States, 63376
Actively Recruiting
14
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States, 63141
Actively Recruiting
15
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
16
Siteman Cancer Center-South County
St Louis, Missouri, United States, 63129
Actively Recruiting
17
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, United States, 63136
Actively Recruiting
18
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, United States, 10032
Actively Recruiting
19
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
20
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
21
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, United States, 37204
Actively Recruiting
22
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
23
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
24
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908
Actively Recruiting
25
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, United States, 23298
Actively Recruiting
26
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, United States, 53718
Actively Recruiting
27
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States, 53792
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here